Market Scenario 

Organ-on-a-chip market was valued at US$ 129.96 million in 2023 and is projected to hit the market valuation of US$ 1,665.91 million by 2032 at a CAGR of 34.34% during the forecast period 2024–2032.

The technology of organ-on-a-chip has proven to be of immense significance to the pharmaceutical as well as the biotechnological industries. It has practically resulted into the transformation of drug discovery, development, and individualization of drugs. This novel concept makes use of microfluidic devices that are able to closely simulate the microarchitecture and functionality of human organs, which render it more reliable and efficient than the otherwise drug testing alternatives. It is worth mentioning that more than 50 companies around the world are fully engaged in the development and commercialization of  organ-on-a-chip systems. Also since 2023, about 1,500 research papers on organ-on-a-chip market have been published however it remains limited to not more than 10 universities offering this as a specialized course or a module. The pharmaceutical industry has embraced OoC technology due to its potentials of drainage drug development and screening. It suffices to say that organ-on-chip market offer a viable solution of testing drugs by closely predicting the bioavailability as well as the pharmacodynamics of the drug. More than 30 registered clinical trials have been conducted that tested the efficacy and safety of drugs on organ-on-a-chip platforms. New applications of these technologies are evidenced by the emergence of lung-on-chip for the study of respiratory diseases, liver-on-chip for drug metabolism and hepatotoxicity, heart-on-chip technologies to measure cardiotoxicity among others.

Furthermore, the development of multi-organ systems in the organ-on-a-chip market enables various mutual effects of different organs to be explored with a better perspective of the scope of drug activity on all organ systems in their entirety. Government and private actions or measures have been critical in developing organ-on-a-chip technology. Since 2012, the National Institutes of Health (NIH) in the United States has funded OoC research projects with over US$ 140 million and the European Union has financed over 20 collaborative projects in this area. Thanks to following projects there were achieved significant results, such as the invention of real time sensors for the purpose of continued cell activity monitoring and the application of 3D bioprinting for enhanced tissue biomimicry. The intellectual property situation has also become very active and as of 2023, there are over 500 patents reported in connection with the OoC technologies.

By contrast, SOT is primarily focused on creating personalized medicine; however, as the organ-on-a-chip market matures, it broadens its scope by integrating other areas such as disease modeling or studying multi-scale biological systems. The possibilities brought by OoC-pharmaceutical and biotechnology systems provide new opportunities for rapid development of therapeutics and increasing reliability of preclinical studies. Continuous enhancements in multi-organ systems, sensor integration and 3D bioprinting suggest that OoC technology will become very helpful throughout the translational research from in vitro testing to human clinical studies. Such developments in this field should not only decrease the dependence on animal testing but also increase the speed and efficiency of overall processes of drug development allowing for more effective and safer pharmaceuticals to be provided on the organ-on-a-chip market.

To Get more Insights,  Request A Free Sample 

Market Dynamics 

Driver Focus: Growing Need for Accurate Human-Mimetic Models

The global pharmaceutical sector is searching for better models that can effectively reproduce human biophysics in order to advance drug discovery and development. Animal testing, simple cell cultures and similar procedures are forgotten in history because they are inadequate in predicting human responses which might lead to unfortunate expensive ‘failures’ late in development. Data showed that mass drug development expenditures to exceed $2.5 billion dollars in 2023 for a single useful drug, highlighting the tendency of booming losses instead of profits. Wherein, organ-on-a-chip market seems to be the solution for this problem since it provides a framework that approximates the human organ system’s intricacies which in turn enhances testing procedures. More than 200 organotypic chips including liver and lung models to aid in metabolism and respiratory disease research were reported in 2023 alone. It is believed that these chips played a significant role in pre-clinical screening of toxicity and minimized adverse events during clinical testing. A study published in 2023 showed that liver-on-a-chip models were able to predict liver toxicity 85% of the times, clearly better than conventional methods have ever.

This trend is further illustrated by the increasing partnership between the academia and the industrial players. For example, in collaboration with a research university in 2023, a top pharmaceutical firm was able to create a heart-on-a-chip which closely replicates cardiac arrhythmia. Such partnerships are important for the development of OoC technology and its wider incorporation into the industry’s drug development processes.

Trend Focus: Integration of Artificial Intelligence with Organ-on-a-Chip Systems

AI and OoC Technologies Fusion Convergence became one of the vivid trends in organ-on-a-chip market. AI boosts the functionality of OoC systems through advanced data comprehension and forecasting technology. This combination makes it possible to continuously observe and interpret the complicated biological responses unfolding in the chips. In 2023, more than 60% of all newly initiated organ on a chip platforms made use of AI algorithms for data processing. For instance, the AI-based kidney-on-a-chip improved specificity of the nephrotoxic effect screening of newly created compounds. An US-based AI startup rolled out in 2023 an AI powered OoC platform that can accurately predict drug induced organ damage with minimal error margin. Besides, training of algorithms also enabled approximation of the disease advancement in the organ chips thus giving further understanding of its pathophysiology. 

This introduction of AI does not only speed up the process of researching but also improves the accuracy of the results obtained in the organ-on-a-chip market. AI generates value from the datasets created by the OoC experiments through identifying detailed features and reactions otherwise regarded as noise during normal analysis. This tendency is expected to deepen with funding for AI installation rising to over US$ 500 million in 2023, what was definitely do not happen before.

Challenge Focus: Limited Standardization Across Different Organ-on-a-ChipPlatforms

The organ-on-a-chip market faces standardization issues across its different platforms. In 2023, a survey showed that OoC devices manufacturers designed more than 70% of devices to have unique shapes, functional materials, and their own protocols. Therefore, this unevenness makes it difficult to harmonize results obtained from different studies and also delays the use of organ on a chip data for approval of new drugs. The use of diverse organ systems for modeling and different proprietary technologies for developing ooc systems make bringing about uniformity complex. For example, while one company may utilize silicone-based chips, another may utilize polymer-based materials which leads to disparities in the cellular response. To counter this drawback, international consortia formed in 2023 aim at developing uniform guidelines regarding the OoC development and testing procedures. Adopting a chip model has potential but FDA argues for a single standard validation process. In 2023, the FDA published a draft guidance document which specified the areas which should be covered in the OoC data included in BA submissions.

Segmental Analysis 

By Product & Services 

Based on product & services, product segment that comprises instruments as well as the OOC devices such as liver on chip, lung on chip, heart on chip devices is currently dominating the organ-on-a-chip market with over 65.12% market share. This is owing to increased use and development in technology. A high demand for these devices has come up as they are more relevant for human models in drug testing and modeling of diseases. The increase in the chronic diseases and the requirement for individualized medicines has increased the utilization of OOC products leading to intensive use in R and D.

In 2023, a number of key industry players in the organ-on-a-chip market have come forward to invest substantially into OOC devices so that new products that are more advanced than the current ones can be developed. Such developments have transformed OOC devices into cheap and easy to use systems which in turn encourages more and more institutions and companies to use them. Such renewed growths in the quality and use of these products propagates the growth of the organ on chip market maintaining it in a highly dynamic state. Moreover, supportive legislation and cooperation between industry and academia have facilitated the uptake of OOC products as opposed to services. The absence of OOC device standards and guidelines in 2023 have resulted in lack of confidence among end-users, thus weakening the procurement of goods. The potential of OOC devices to provide better predictive human models that reduce the cost and time required for drug development have made them popular options hence justifying the growth of this product segment in the market.

By Application 

Based on application, organ-on-a-chip market finds its largest demand in drug discovery due to its potential to revolutionize the drug development process. In 2023, the segment held over 64.32% market share. The pharmaceutical sector operates under considerable constraints to decrease both the time and capital expenditure incurred while completing the new drug life cycle. OOC devices are beneficial in that they provide accurate human organ models whereby drug responses are more accurate than when carrying out the studies on animal models. With this kind of increased precision, there is a reduced probability of clinical trial termination in later stages which translates to a saving of resources by the companies.

One reason that makes organ-on-a-chip technology appealing is its potential to enhance the effectiveness of its applications in drug development. Among the works from 2023, important accomplishments in microfluidics and biomaterials allowing OOC platforms to be developed that are capable of closely modeling complex human organs have also been reported. Therefore, it is possible to create normal physiological conditions in which numerous drugs might be screened at once, and in this way promising drugs can be identified more rapidly. The great flexibility in the designs of devices in organ-on-a-chip marketplace allows the models to direct and concentrate on certain diseases so that the understanding of the mechanisms of those diseases is improved, while new treatments may be established.

Out of the key factors that are contributing towards the growth the solid financing of organ-on-a-chip projects, collaborations of pharmaceutical and technology companies, and favorable policy regimes. In 2023, a number of regulators have appeared more willing to accept the data that emerges from OOC studies since they deem it helpful in predicting how people are expected to respond. The organ-on-a-chip market’s capacity to generate outcomes rapidly, and its ability to reduce animal testing requirements as mentioned previously, are further characteristics which have made it possible for companies to make necessary adjustments and improvements in order to satisfy the demand of the pharmaceutical market.

By End Users

Pharmaceutical and biotechnology companies are the primary consumers of the organ-on-a-chip market due to their critical need for advanced tools that enhance drug development efficiency. In 2023, these companies are actively seeking technologies that can reduce the high costs and lengthy timelines associated with bringing new drugs to market. organ on a chip devices provide highly predictive human organ models that can identify potential drug failures early in the development process, thereby minimizing costly late-stage clinical trial failures.

These companies lead the market as they have the resources and infrastructure to adopt and integrate organ on a chip technology extensively. In 2023, significant investments have been made by pharmaceutical giants to incorporate OOC platforms into their R&D pipelines, support the organ-on-a-chip market growth further. Collaborations between OOC developers and pharmaceutical companies have resulted in tailored OOC systems that meet specific research needs, further solidifying their reliance on these technologies. The ability to conduct more efficient and ethical research, with reduced use of animal models, aligns with the evolving goals of these industries. Moreover, the global scale and influence of pharmaceutical and biotechnology companies contribute to their control of the highest market share. In 2023, their widespread adoption of OOC devices has set industry standards and driven market trends. Their emphasis on innovation and improving success rates in drug development keeps them at the forefront of utilizing cutting-edge technologies like OOC, reinforcing their position as leading end-users in the market.

 To Understand More About this Research:  Request A Free Sample 

Regional Analysis 

The organ-on-a-chip market has expanded greatly, and the most prominent region is North America, more specifically, the United States. The region constituting over 46% of the global organ-on-a-chip market, it is fueled by a huge amount of funding and an extensive research community. In 2023, the federal budget for the National Institutes of Health in the United States was US$ 45 billion, out of which US$ 2 billion was set aside for biomaterials and organ-on-chip systems. The same year, private companies raised more than US$ 35 billion in venture capital financing further demonstrating a strong appetite for OoC technologies. The US market for OoC seems to be booming with approximately 50 companies producing the technology and many new players entering the scene. Moreover, American authors managed to publish more than 200 peer-reviewed manuscripts on the subject of the OoC technology in 2023, which indicates a development of the tissue engineering field from an academic perspective. There is also support from regulators, with the FDA already announcing a US$5 million project to use the OoC technology in drug evaluation, which further emphasizes the region’s dominance.

On the other hand, the Asia Pacific region is positioning itself to be the world's key player in the organ-on-a-chip market, with heavy support from government funding and research projects. Over the next five years, China has pledged to invest US$15 billion in biotechnological advancement with a focus primarily on organ-on-chip technology. This has resulted in the number of Chinese papers on the topic increasing to over 120 by 2023. Significant amounts have also been allocated in Japan exceeding ¥10 billion for regenerative medicine and organ-on-chip technology R&D. At present, South Korea opened its first national organ-on-chip research facility in the Seoul National University with a price tag of 100 million dollars. At the same time, the working government in Australia has made a provision of AUD 5 million for university research activities on OoC models. The incorporation of more than 25 start-ups focusing on organ-on chips in 2023 shows the growth of more entrepreneurial activities in the region as well as increased attention and interest in the industry.

Top Players in Organ on a Chip Market

• Emulate, INC.
• Mimetas B.V.
• Valo Health
• AIM Biotech Pte. Ltd.
• AxoSim, Inc.
• InSphero
• CN Bio Innovations Ltd
• SynVivo, Inc.
• TissUse GmbH
• AlveoliX AG
• Other Prominent Players

Market Segmentation Overview:

By Product & Services

• Products
  • Instruments
  • Organ-on-a-Chip Devices
    • Liver-on-a-Chip
    • Lung-on-a-Chip
    • Intestine-on-a-Chip
    • Kidney-on-a-Chip
    • Heart-on-a-Chip
    • Others
• Services

By Application

• Drug Discovery
• Toxicology Research
• Others

By End Users

• Academic and Research Institutes
• Pharmaceutical & Biotechnology Companies
• Others

By Region

• North America
  • The U.S.
  • Canada
  • Mexico
• Europe
  • Western Europe
    • The UK
    • Germany
    • France
    • Italy
    • Spain
    • Rest of Western Europe
  • Eastern Europe
    • Poland
    • Russia
    • Rest of Eastern Europe
• Asia Pacific
  • China
  • India
  • Japan
  • Australia & New Zealand
  • South Korea
  • ASEAN
  • Rest of Asia Pacific
• Middle East & Africa (MEA)
  • Saudi Arabia
  • South Africa
  • UAE
  • Rest of MEA
• South America
  • Argentina
  • Brazil
  • Rest of South America